Usefulness of circulating EPAC1 as biomarkers of therapeutic response to GLP-1 receptor agonists.

MLA

Hernández, Cristina, et al. “Usefulness of Circulating EPAC1 as Biomarkers of Therapeutic Response to GLP-1 Receptor Agonists.” Acta Diabetologica, vol. 59, no. 11, Nov. 2022, pp. 1437–42. EBSCOhost, https://doi.org/10.1007/s00592-022-01928-6.

APA

Hernández, C., Gómez-Peralta, F., Simó-Servat, O., García-Ramírez, M., Abreu, C., Gómez-Rodríguez, S., & Simó, R. (2022). Usefulness of circulating EPAC1 as biomarkers of therapeutic response to GLP-1 receptor agonists. Acta Diabetologica, 59(11), 1437–1442. https://doi.org/10.1007/s00592-022-01928-6

Chicago

Hernández, Cristina, Fernando Gómez-Peralta, Olga Simó-Servat, Marta García-Ramírez, Cristina Abreu, Sara Gómez-Rodríguez, and Rafael Simó. 2022. “Usefulness of Circulating EPAC1 as Biomarkers of Therapeutic Response to GLP-1 Receptor Agonists.” Acta Diabetologica 59 (11): 1437–42. doi:10.1007/s00592-022-01928-6.